A detailed history of Gilder Gagnon Howe & CO LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 23,206 shares of EXAS stock, worth $1.35 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
23,206
Previous 23,631 1.8%
Holding current value
$1.35 Million
Previous $998,000 58.32%
% of portfolio
0.02%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.43 - $70.83 $18,032 - $30,102
-425 Reduced 1.8%
23,206 $1.58 Million
Q2 2024

Aug 14, 2024

SELL
$41.33 - $74.26 $17,358 - $31,189
-420 Reduced 1.75%
23,631 $998,000
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $6.86 Million - $9 Million
-121,951 Reduced 83.53%
24,051 $1.66 Million
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $1.92 Million - $2.46 Million
-32,433 Reduced 18.18%
146,002 $10.8 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $13,188 - $19,808
-200 Reduced 0.11%
178,435 $12.2 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $2.26 Million - $3.43 Million
36,120 Added 25.34%
178,635 $16.8 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $64,839 - $97,237
1,374 Added 0.97%
142,515 $9.66 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $275,669 - $482,761
9,083 Added 6.88%
141,141 $6.99 Million
Q3 2022

Nov 14, 2022

SELL
$31.97 - $49.37 $15.8 Million - $24.4 Million
-494,925 Reduced 78.94%
132,058 $4.29 Million
Q2 2022

Aug 15, 2022

SELL
$35.61 - $76.23 $27 Million - $57.8 Million
-757,613 Reduced 54.72%
626,983 $24.7 Million
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $1.39 Million - $1.99 Million
-24,076 Reduced 1.71%
1,384,596 $96.8 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $1.25 Million - $1.73 Million
-17,217 Reduced 1.21%
1,408,672 $110 Million
Q3 2021

Nov 15, 2021

SELL
$90.24 - $124.05 $1.76 Million - $2.42 Million
-19,489 Reduced 1.35%
1,425,889 $136 Million
Q2 2021

Aug 16, 2021

SELL
$93.66 - $139.27 $2.19 Million - $3.26 Million
-23,423 Reduced 1.59%
1,445,378 $180 Million
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $14 Million - $18.6 Million
119,772 Added 8.88%
1,468,801 $194 Million
Q4 2020

Feb 16, 2021

SELL
$99.61 - $142.12 $1.38 Million - $1.96 Million
-13,819 Reduced 1.01%
1,349,029 $179 Million
Q3 2020

Nov 16, 2020

SELL
$72.92 - $102.01 $3.08 Million - $4.3 Million
-42,178 Reduced 3.0%
1,362,848 $139 Million
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $8.75 Million - $14.6 Million
-157,010 Reduced 10.05%
1,405,026 $122 Million
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $7.13 Million - $19.7 Million
-188,173 Reduced 10.75%
1,562,036 $90.6 Million
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $4.03 Million - $5.18 Million
-51,885 Reduced 2.88%
1,750,209 $162 Million
Q3 2019

Nov 14, 2019

SELL
$90.37 - $122.49 $7.79 Million - $10.6 Million
-86,193 Reduced 4.56%
1,802,094 $163 Million
Q2 2019

Aug 13, 2019

SELL
$89.51 - $118.04 $10.5 Million - $13.8 Million
-117,107 Reduced 5.84%
1,888,287 $223 Million
Q1 2019

May 17, 2019

BUY
$61.98 - $96.5 $6.67 Million - $10.4 Million
107,603 Added 5.67%
2,005,394 $174 Million
Q4 2018

Feb 14, 2019

SELL
$56.04 - $82.66 $2.87 Million - $4.23 Million
-51,189 Reduced 2.63%
1,897,791 $120 Million
Q3 2018

Oct 30, 2018

SELL
$48.29 - $80.6 $1.01 Million - $1.69 Million
-21,009 Reduced 1.07%
1,948,980 $154 Million
Q2 2018

Jul 31, 2018

SELL
$37.84 - $69.96 $1.14 Million - $2.1 Million
-30,048 Reduced 1.5%
1,969,989 $118 Million
Q1 2018

Apr 30, 2018

SELL
$39.82 - $57.53 $3.79 Million - $5.47 Million
-95,161 Reduced 4.54%
2,000,037 $80.7 Million
Q4 2017

Jan 31, 2018

SELL
$46.49 - $60.51 $20.7 Million - $26.9 Million
-444,254 Reduced 17.49%
2,095,198 $110 Million
Q3 2017

Nov 06, 2017

BUY
$37.05 - $47.12 $94.1 Million - $120 Million
2,539,452
2,539,452 $120 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.